Chemopreventive and therapeutic potential of tea polyphenols in hepatocellular cancer

Nutrition and Cancer

Volumn 65, Issue 3, 2013, Pages 329-344

  Darvesh, Altaf S ^a   Bishayee, Anupam ^b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b American University of Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; ALPHA FETOPROTEIN; CATECHIN; EPIGALLOCATECHIN GALLATE; KAEMPFEROL; NITROSAMINE; POLYPHENOL DERIVATIVE; QUERCETIN; SORAFENIB; THEAFLAVIN;

ANTINEOPLASTIC ACTIVITY; CANCER RISK; CANCER SURGERY; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHEMICAL ANALYSIS; CHEMOPROPHYLAXIS; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MEGADOSE; DRUG SCREENING; HEPATOMA CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAXIMUM PLASMA CONCENTRATION; MULTIMODALITY CANCER THERAPY; NONHUMAN; OXIDATIVE STRESS; REVIEW; SYSTEMATIC REVIEW; TEA; UNSPECIFIED SIDE EFFECT; XENOGRAFT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; BIOLOGICAL AVAILABILITY; CATECHIN; CHEMOPREVENTION; DISEASE MODELS, ANIMAL; HUMANS; LIVER NEOPLASMS; MICE; POLYPHENOLS; TEA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

CAMELLIA SINENSIS;

EID: 84876118263     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2013.767367     Document Type: Review

References (164)

1. Stan, S D, Kar, S, Stoner, G D, and, Singh, S V. 2008. Bioactive food components and cancer risk reduction. J Cell Biochem, 104: 339-356.
2. Gullett, N P, Ruhul, Amin ARM, Bayraktar, S, Pezzuto, J M, Shin, D M. 2010. Cancer prevention with natural compounds. Semin Oncol, 37: 258-281.
3. Huang, W Y, Cai, Y Z, and, Zhang, Y. 2010. Natural phenolic compounds from medicinal herbs and dietary plants: potential use for cancer prevention. Nutr Cancer, 62: 1-20.
4. Bishayee, A. 2012. Editorial: current advances in cancer prevention and treatment by natural products. Curr Pharm Biotechnol, 13: 115-116.
5. Catalgol, B, Batirel, S, Taga, Y, Ozer, N K. 2012. Resveratrol: French paradox revisited. Front Pharmacol, 3 (141)
6. Zaveri, N T. 2006. Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications. Life Sci, 78: 2073-2080.
7. Rossi, L, Mazzitelli, S, Arciello, M, Capo, C R, and, Rotilio, G. 2008. Benefits from dietary polyphenols from brain aging and Alzheimer's disease. Neurochem Res, 33: 2390-2400.
8. Bengmark, S, Mesa, M D, and, Gil, A. 2009. Plant derived health: the effects of turmeric and curcuminoids. Nutr Hosp, 24: 273-281.
9. Bishayee, A. 2009. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res, 2: 409-418.
10. Crozier, A, Jaganath, I B, and, Clifford, M N. 2009. Dietary phenolics: chemistry, bio-availability and effects on health. Nat Prod Rep, 26: 1001-1043.
11. Bishayee, A, and, Darvesh, A S. 2010. " Oxidative stress in cancer and neurodegenerative diseases: prevention and treatment by dietary antioxidants ". In Handbook of Free Radicals, Types and Effects, Edited by: Kozyrev, D and Slutsky, V. 1-67. Hauppauge, NY: Nova Science Publishers, Inc.
12. Darvesh, A S, Carroll, R T, Bishayee, A, Novotny, N A, Geldenhuys, W J. 2010. Oxidative stress and Alzheimer's disease: dietary polyphenols as potential therapeutic agents. Expert Rev Neurother, 10: 729-745.
13. Izzi, V, Masuelli, L, Tresoldi, I, Sacchetti, P, Modesti, A. 2012. The effects of dietary flavonoids on the regulation of redox inflammatory networks. Front Biosci, 17: 2396-2418.
14. Lambert, J D, Hong, J, and, Yang, G Y. 2005. Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations. Am J Clin Nutr, 81: 284-291.
15. Sang, S, Hou, Z, Lambert, J D, and, Yang, C S. 2005. Redox properties of tea polyphenols and related biological activities. Antioxid Redox Signal, 7: 1704-1714.
16. Yang, C S, Lambert, J D, Ju, J, Lu, G, and, Sang, S. 2007. Tea and cancer prevention: molecular mechanisms and human relevance. Toxicol Appl Pharmacol, 224: 265-273.
17. Bisht, K, Wagner, K H, and, Bulmer, A C. 2009. Curcumin, resveratrol and flavonoids as anti-inflammatory, cyto- and DNA-protective dietary compounds. Toxicology, 278: 88-100.
18. Jagtap, S, Meganathan, K, Wagh, V, Winkler, J, Hescheler, J. 2009. Chemoprotective mechanism of the natural compounds, epigallocatechin-3-O- gallate, quercetin and curcumin against cancer and cardiovascular diseases. Curr Med Chem, 16: 1451-1462.
19. Sarkar, F H, Li, Y, Wang, Z, and, Kong, D. 2009. Cellular signaling perturbation by natural products. Cell Signal, 21: 1541-1547.
20. González-Gallego, J, García-Mediavilla, M V, Sánchez-Campos, S, and, Tuñón, M J. 2010. Fruit polyphenols, immunity and inflammation. Br J Nutr, 104: S15-S27.
21. Mandel, S A, and, Youdim, M B. 2012. In the rush for green gold: can green tea delay age-progressive brain neurodegeneration?. Recent Pat CNS Drug Discov, 7: 205-217.
22. Mandel, S A, Avramovich-Tirosh, Y, Reznichenko, L, Zheng, H, Weinreb, O. 2005. Multifunctional activities of green tea catechins in neuroprotection. Neurosignals, 14: 46-60.
23. Yang, C S, Ju, J, and, Lu, G. 2008. Cancer prevention by tea and tea polyphenols. Asia Pac J Clin Nutr, 17: 245-248.
24. Butt, M S, and, Sultan, M T. 2009. Green tea: Nature's defense against malignancies. Crit Rev Food Sci Nutr, 49: 463-473.
25. Clement, Y. 2009. Can green tea do that? A literature review of the clinical evidence. Prev Med, 49: 83-87.
26. Grove, K A, and, Lambert, J D. 2010. Laboratory, epidemiological, and human intervention studies show that tea (Camellia sinensis) may be useful in the prevention of obesity. J Nutr, 140: 446-453.
27. Rains, T M, Agarwal, S, and, Maki, K C. 2011. Antiobesity effects of green tea catechins: a mechanistic review. J Nutr Biochem, 22: 1-7.
28. Li, W, Mei, X, and, Tu, Y Y. 2012. Effects of tea polyphenols and their polymers on MAPK signaling pathways in cancer research. Mini Rev Med Chem, 12: 120-126.
29. Davalli, P, Rizzi, F, Caporali, A, Pellacani, D, Davoli, S. 2012. Anticancer activity of green tea polyphenols in prostate gland. Oxid Med Cell Longev,. 984219, 2012
30. Kanwar, J, Taskeen, M, Mohammad, I, Huo, C, Chan, T H. 2012. Recent advances on tea polyphenols. Front Biosci, 4: 111-131.
31. Katiyar, S K, and, Mukhtar, H. 1997. Tea antioxidants in cancer prevention. J Cell Biochem Suppl, 27: 59-67.
32. Landau, J M, Lambert, J D, Lee, M J, and, Yang, C S. 2006. " Cancer prevention by tea and tea constituents ". In Carcinogenic and Anticarcinogenic Food Components, Edited by: Baer-Dubowska, W, Bartoszek, A and Malejka-Giganti, D. 219-237. Boca Raton, FL: Taylor and Francis Group CRC Press.
33. Katiyar, S, Elmets, C A, and, Katiyar, S K. 2007. Green tea and skin cancer: photoimmunology, angiogenesis and DNA repair. J Nutr Biochem, 18: 287-296.
34. Khan, N, Adhami, V M, and, Mukhtar, H. 2009. Review: green tea polyphenols in chemoprevention of prostate cancer: preclinical and clinical studies. Nutr Cancer, 61: 836-841.
35. Johnson, J J, Bailey, H H, and, Mukhtar, H. 2010. Green tea polyphenols for prostate cancer chemoprevention: a translational perspective. Phytomedicine, 17: 3-13.
36. Kim, J W, Ruhul Amin, A RM, and, Shin, D M. 2010. Chemoprevention of head and neck cancer with green tea polyphenols. Cancer Prev Res, 3: 900-909.
37. Link, A, Balaguer, F, and, Goel, A. 2010. Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochem Pharmacol, 80: 1771-1792.
38. Gupta, S, Ahmed, N, and, Mukhtar, H. 1999. Prostate cancer chemoprevention by green tea. Semin Urol Oncol, 17: 70-76.
39. Shukla, Y. 2007. Tea and cancer chemoprevention: a comprehensive review. Asian Pacific J Cancer Prev, 8: 155-166.
40. Pandey, M, and, Gupta, S. 2009. Green tea and prostate cancer: from bench to clinic. Front Biosci, 1: 13-25.
41. Yang, C S, Wang, X, Lu, G, and, Picinich, S C. 2009. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer, 9: 429-439.
42. Schütte, K, Bornschein, J, and, Malfertheiner, P. 2009. Hepatocellular carcinoma- epidemiological trends and risk factors. Dig Dis, 27: 80-92.
43. Thun, M J, DeLancey, J O, Center, M M, Jemal, A, and, Ward, E M. 2010. The global burden of cancer: priorities for prevention. Carcinogenesis, 31: 100-110.
44. Sherman, M. 2005. Hepatocellular carcinoma: epidemiology, risk factors and screening. Semin Liver Dis, 25: 143-154.
45. Jemal, A, Bray, F, Center, M M, Ferlay, J, Ward, E. 2011. Global cancer statistics. CA Cancer J Clin, 61: 69-90.
46. Chen, J. 2012. Trends in incidence of liver cancer and its primary prevention in China. Chin J Clin Hepatol, 4: 256-260.
47. Siegel, R, Naishadham, D, and, Jemal, A. 2012. Cancer statistics. CA Cancer J Clin, 62: 10-29. 2012
48. Bartsch, H, and, Montesano, R. 1984. Relevance of nitrosamines to human cancer. Carcinogenesis, 5: 1381-1393.
49. Okuda, K. 2000. Hepatocellular carcinoma. J Hepatol, 32: 225-237.
50. Bruix, J, and, Llovet, J M. 2003. Hepatis B virus and hepatocellular carcinoma. J Hepatol, 39: S59-S63.
51. Kensler, T W, Egner, P A, and, Wang, J B. 2004. Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology, 127: S310-S318.
52. Ribes, J, Clèries, R, Esteban, L, Moreno, V, and, Bosch, F X. 2008. The influence of alcohol consumption and hepatitis B and C infections on the risk of liver cancer in Europe. J Hepatol, 49: 233-242.
53. Llovet, J M, Burroughs, A, and, Bruix, J. 2003. Hepatocellular carcinoma. Lancet, 362: 1907-1917.
54. Mazzaferro, V, Regalia, E, Doci, R, Andreola, S, Pulvirenti, A. 1996. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Eng J Med, 344: 693-699.
55. Llovet, J M, Ricci, S, and, Mazzaferro, V. 2008. Sorafenib in advanced hepatocellular carcinoma. N Eng J Med, 359: 378-390.
56. Je, Y, Schutz, F AB, and, Choueiri, T K. 2009. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and mata-analysis of clinical trials. Lancet Oncol, 10: 967-974.
57. Lu, S C. 2010. Where are we in the chemoprevention of hepatocellular carcinoma?. Hepatology, 51: 734-736.
58. Okuno, M, Kojima, S, and, Moriwaki, H. 2001. Chemoprevention of hepatocellular carcinoma: concept, progress, and perspectives. J Gastroenterol Hepatol, 16: 1329-1335.
59. Kensler, T W, Qian, G S, Chen, J G, and, Groopman, J D. 2003. Translation strategies for cancer prevention in liver. Nat Rev Cancer, 3: 321-329.
60. Ha, H L, Shin, H J, Feitelson, M A, and, Yu, D Y. 2010. Oxidative stress and antioxidants in hepatic pathogenesis. World J Gastroenterol, 16: 6035-6043.
61. Klaunig, J E, and, Kamedulis, L M. 2004. The oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol, 44: 239-267.
62. Sánchez-Pérez, Y, Carrasco-Legleu, C, García- Cuellar, C, Pérez-Carreón, J, Hernández-García, S. 2005. Oxidative stress in carcinogenesis. Correlation between lipid peroxidation and induction of preneoplastic lesions in rat hepatocarcinogenesis. Cancer Lett, 217: 25-32.
63. Mantovani, A, Allavena, P, Sica, A, and, Balkwill, F. 2008. Cancer-related inflammation. Nature, 454: 436-444.
64. Kundu, J K, and, Surh, Y J. 2008. Inflammation: gearing the journey to cancer. Mut Res, 659: 15-30.
65. Llovet, J M, and, Bruix, J. 2008. Molecular targeted therapies in hepatocellular carcinoma. Hepatology, 48: 1312-1327.
66. Prieto, J. 2008. Inflammation, HCC and sex: IL-6 in the centre of the triangle. J Hepatol, 48: 380-381.
67. Nejak-Bowen, K N, and, Monga, S P. 2011. Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin Cancer Biol, 21: 44-58.
68. Pang, R, Tse, E, and, Poon, R TP. 2006. Molecular pathways in hepatocellular carcinoma. Cancer Lett, 240: 157-169.
69. Wong, C M, and, Ng, I OL. 2007. Molecular pathogenesis of hepatocellular carcinoma. Liver Int, 28: 160-174.
70. Frau, M, Biasi, F, and, Feo, F. 2010. Prognositc markers and putative therapeutic targets for hepatocellular carcinoma. Mol Aspects Med, 31: 179-193.
71. Hoshida, Y, Toffanin, S, Lachenmayer, A, Villanueva, A, Minguez, B. 2010. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin. Liver Dis, 30: 35-51.
72. Whittaker, S, Marais, R, and, Zhu, A X. 2010. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene, 29: 4989-5005.
73. Simile, M M, Frau, M, Pascale, R M, and, Feo, F. 2011. New putative prognostic markers and therapeutic targets for the molecular approach to treatment of hepatocellular carcinoma. J Expt Integ Med, 1: 85-97.
74. Lee, K W, Lee, H J, and, Lee, C Y. 2004. Vitamins, phytochemicals, diets, and their implementation in cancer chemoprevention. Crit Rev Food Sci Nutr, 44: 437-452.
75. Lee, K W, and, Lee, H J. 2006. The roles of polyphenols in cancer chemoprevention. Biofactors, 26: 105-121.
76. de Kok, T M, de Waard, P, Wilms, L C, and, van Breda, S G. 2010. Antioxidative and antigenotoxic properties of vegetables and dietary phytochemicals: the value of genomics biomarkers in molecular epidemiology. Mol Nutr Food Res, 54: 208-217.
77. Balentine, D A, Wiseman, S A, and, Bouwens, L C. 1997. The chemistry of tea flavonoids. Crit Rev Food Sci Nutr, 37: 693-704.
78. Lambert, J D, and, Elias, R J. 2010. The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention. Arch Biochem Biophys, 501: 65-72.
79. Lambert, J D, Sang, S, and, Yang, C S. 2007. Biotrasnformation of green tea polyphenols and the biological activities of those metabolites. Mol Pharm, 6: 819-825.
80. Lambert, J D, Sang, S, Lu, A Y, and, Yang, C S. 2007. Metabolism of dietary polyphenols and possible interactions with drugs. Curr Drug Met, 8: 499-507.
81. Sang, S, Lambert, J D, Ho, C T, and, Yang, C S. 2011. The chemistry and biotransformation of tea constituents. Pharmacol Res, 64: 87-99.
82. Lambert, J D, and, Yang, C S. 2003. Cancer chemopreventive activity and bioavailability of tea and tea polyphenols. Mut Res, 524: 201-208.
83. Yang, C S, Sang, S, Lambert, J D, and, Lee, M J. 2008. Bioavailability issues in studying the health effects of plant polyphenolic compounds. Mol Nutr Food Res, 52: S139-S151.
84. Fu, Z, Zhen, W, Yuskavage, J, and, Liu, D. 2010. Epigallocatechin gallate delays the onset of type 1 diabetes in spontaneous non-obese diabetic mice. Br J Nutr, 105: 1218-1225.
85. Nagle, D G, Ferreira, D, and, Zhou, YD. 2006. Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives. Phytochemistry, 67: 1849-1855.
86. Carlson, J R, Bauer, B A, Vincent, A, Limburg, P J, and, Wilson, T. 2007. Reading the tea leaves: anticarcinogenic properties of (-)-epigallocatechin-3- gallate. Mayo Clin Proc, 82: 725-732.
87. Henning, S M, Wang, P, and, Heber, D. 2011. Chemopreventive effects of tea in prostate cancer: green tea versus black tea. Mol Nutr Food Res, 55: 905-920.
88. Lambert, J D, and, Yang, C S. 2003. Mechanisms of cancer prevention by tea constituents. J Nutr, 133: 3262S-3267S.
89. Hou, Z, Lambert, J D, Chin, K V, and, Yang, C S. 2004. Effects of tea polyphenols on signal transduction pathways related to cancer chemoprevention. Mut Res, 555: 3-19.
90. Ju, J, Lu, G, Lambert, J D, and, Yang, C S. 2007. Inhibition of carcinogenesis by tea constituents. Semin Cancer Biol, 17: 395-402.
91. Yang, C S, Lambert, J D, and, Sang, S. 2009. Antioxidative and anti-carcinogenic activities of tea polyphenols. Arch Toxicol, 83: 11-21.
92. Thakur, V S, Gupta, K, and, Gupta, S. 2012. The chemopreventive and chemotherapeutic potentials of tea polyphenols. Curr Pharm Biotechnol, 13: 191-199.
93. Mann, C D, Neal, C P, Garcea, G, Manson, M M, Dennison, A R. 2009. Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis. Eur J Cancer Prev, 18: 13-35.
94. Yang, C S, and, Wang, X. 2010. Green tea and cancer prevention. Nutr Cancer, 62: 931-937.
95. Katiyar, S K. 2003. Skin photoprotection by green tea: antioxidant and immunomodulatory effects. Curr Drug Targets Immune Endocr Metabol Disord, 3: 234-242.
96. Gupta, S, Saha, B, and, Giri, A K. 2002. Comparative antimutagenic and anticlastogenic effects of green tea and black tea: a review. Mutat Res, 512: 37-65.
97. Katiyar, S K. 2006. Matrix metalloproteinases in cancer metastasis: molecular targets for prostate cancer prevention by green tea polyphenols and grape seed proanthocyanidins. Endocr Metab Immune Disord Drug Targets, 6: 17-24.
98. Yang, C S, Sang, S, Lambert, J D, Hou, Z, Ju, J. 2006. Possible mechanisms of the cancer-preventive activities of green tea. Mol Nutr Food Res, 50: 170-175.
99. Yang, C S, Lambert, J D, Hou, Z, Ju, J, Lu, G. 2006. Molecular targets for the cancer preventive activity of tea polyphenols. Mol Carcinogenesis, 45: 431-435.
100. Yang, H, Landis-Piwowar, K, Chan, TH, and, Dou, Q P. 2011. Green tea polyphenols as proteasome inhibitors: implication in chemoprevention. Curr Cancer Drug Targets, 11: 296-306.
101. Patra, S K, Rizzi, F, Silva, A, Rugina, D O, and, Bettuzzi, S. 2008. Molecular targets of (-)-epigallocatechin-3-gallate (EGCG): specificity and interaction with membrane lipid rafts. J Physiol Pharmacol, 59: 217-235.
102. Shimizu, M, Shirakami, Y, and, Moriwaki, H. 2008. Targeting receptor tyrosine kinases for chemoprevention by green tea catechin, EGCG. Int J Mol Sci, 9: 1034-1049.
103. Tachibana, H. 2009. Molecular basis for cancer chemoprevention by green tea polyphenol EGCG. Forum Nutr, 61: 156-161.
104. Singh, B N, Shankar, S, and, Srivastava, R K. 2011. Green tea catechin, epigallocatechin-3-gallate (EGCG): Mechanisms, perspectives and clinical applications. Biochem Pharmacol, 82: 1807-1821.
105. Boehm, K. 2010. Cochrane reviews-in their own words: green tea for the prevention of cancer. J Evid Based Med, 3 (53)
106. Nair, H B, Sung, B, Yadav, V R, Kannappan, R, Chaturvedi, M M. 2010. Delivery of anti-inflammatory nutraceuticals by nanoparticles for the prevention and treatment of cancer. Biochem Pharmacol, 80: 1833-1843.
107. Bode, A M, and, Dong, Z. 2009. Epigallocatechin 3-gallate and green tea catechins: united they work, divided they fail. Cancer Prev Res, 2: 514-517.
108. Suganuma, M, Saha, A, and, Fujiki, H. 2011. New cancer treatment strategy using combination of green tea catechins and anticancer drugs. Cancer Sci, 102: 317-323.
109. Mazzanti, G, Menniti-Ippolito, F, Moro, P A, Cassetti, F, Raschetti, R. 2009. Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol, 65: 331-341.
110. Lambert, J D, Kennett, M J, Sang, S, Reuhl, K R, Ju, J. 2010. Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice. Food Chem Toxicol, 48: 409-416.
111. Nishida, H, Omori, M, Fukutomi, Y, Ninomiya, M, Nishiwaki, S. 1994. Inhibitory effects of (-)-epigallocatechin gallate on spontaneous hepatoma in C3H/HeNCrj mice and human hepatoma-derived PLC/PRF/5 cells. Jpn J Cancer Res, 85: 221-225.
112. Takada, M, Ku, Y, Toyama, H, Suzuki, Y, and, Kuroda, Y. 2002. Suppressive effects of tea polyphenol and conformational changes with receptor for advanced glycation end products (RAGE) expression in human hepatoma cells. Hepatogastroenterology, 49: 928-931.
113. Wei, D Z, Yang, J Y, Liu, J W, and, Tong, W Y. 2003. Inhibition of liver cell proliferation and migration by a combination of (-)-epigallocatechin-3- gallate and ascorbic acid. J Chemother, 15: 591-595.
114. Ramirez-Mares, M V, Chandra, S, and, de Mejia, E G. 2004. In vitro chemopreventive activity of Camellia sinensis, Ilex paraguarienis and Aridsia compressa tea extracts and selected polyphenols. Mutat Res, 554: 53-65.
115. Sakata, R, Ueno, T, Nakamura, T, Sakamoto, M, Torimura, T. 2004. Green tea polyphenol epigallocatechin-3-gallate inhibits platelet derived growth factor-induced proliferation of human hepatic stellate cell line LI90. J Hepatol, 40: 52-59.
116. Kaufmann, R, Henklein, P, Henklein, P, and, Settmacher, U. 2009. Green tea polyphenol epigallocatechin-3-gallate inhibits thrombin-induced hepatocellular carcinoma cell invasion and p42/p44-MAPKinase activation. Oncol Rep, 21: 1261-1267.
117. Shirakami, Y, Shimizu, M, Adachi, S, Sakai, H, Nakagawa, T. 2009. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis. Cancer Sci, 100: 1957-1962.
118. Liang, G, Tang, A, Lin, X, Li, L, Zhang, S. 2010. Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer. Int J Oncol, 37: 111-123.
119. Tang, H H, Zhou, M, and, Liang, G. 2008. Impact of epigallocatechin gallate on gene expression profiles of human hepatocellular carcinoma cell lines BEL7404/ADM and BEL7402/5-FU. Ai Zheng, 27: 1056-1064.
120. Hayes, C J, Whittaker, B P, Watson, S A, and, Grabowska, A M. 2006. Synthesis and preliminary anticancer activity studies of C4 and C8-modified derivatives of catechin gallate (CG) and epicatechin gallate (ECG). J Org Chem, 71: 9701-9712.
121. Kuo, P L, and, Lin, C C. 2003. Green tea constituent (-)- epigallocatechin-3-gallate inhibits HepG2 cell proliferation and induces apoptosis through p53-dependent and fas-mediated pathways. J Biomed Sci, 10: 219-227.
122. Nishikawa, T, Nakajima, T, Moriguchi, M, Jo, M, Sekoguchi, S. 2006. A green tea polyphenol, epigallocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of Bcl-2 family proteins. J Hepatol, 44: 1074-1082.
123. Lin, S C, Li, W C, Shih, J W, Hong, K F, Pan, Y R. 2006. The tea polyphenol EGCG and EGC repress mRNA expression of human telomerase reverse transcriptase (hTERT) in carcinoma cells. Cancer Lett, 236: 80-88.
124. Newell, A M, Yousef, G G, Lila, M A, Ramírez-Mares, M V, and, de Mejia, E G. 2010. Comparative in vitro bioactivities of tea extracts from six species of Ardisia and their effect on growth inhibition of HepG2 cells. J Ethnopharmacol, 130: 536-544.
125. Roomi, M W, Roomi, N W, Kalinovsky, T, Niedzwiecki, A, and, Rath, M. 2010. In vivo and in vitro effect of a nutrient mixture on hepatocarcinoma cell line SK-Hep-1. Exp Oncol, 32: 84-91.
126. Tu, Y Y, Tang, A B, and, Watanabe, N. 2004. The theaflavin monomers inhibit the cancer cells growth in vitro. Acta Biochim Biophys Sinica, 36: 508-512.
127. Murugan, R S, Priyadarsini, R V, Ramalingam, K, Hara, Y, Karunagaran, D. 2010. Intrinsic apoptosis and NF-κB signaling are potential molecular targets for chemoprevention by black tea polyphenols in HepG2 cells in vitro and in a rat hepatocarcinogenesis model in vivo. Food Chem Toxicol, 48: 3281-3287.
128. Chen, Zy, Yan, R Q, Qin, G Z, and, Qin, L L. 1987. Effect of six edible plants on the development of AFB 1-induced γ-glutamultranspeptidase positive hepatocyte foci in rats. Zhonghua Zhong Liu Za Zhi, 9: 109-111.
129. Li, Y, Yan, R Q, Qin, G Z, Qin, LL, and, Duan, X X. 1991. " Reliability of a short-term test for hepatocarcinogenesis induced by aflatoxin B 1 ". In Relevance to Human Cancer of N-Nitroso Compounds, Tobacco Smoke and Mycotixins, Edited by: ONeill, I K, Chen, J and Bartsch, H. 431-433. Lyon, France: International Agency for Research on Cancer.
130. Qin, G, Gopalan-Kriczky, P, Su, J, Ning, Y, and, Lotlikar, P D. 1997. Inhibition of aflatoxin B 1-induced initiation of hepatocarcinogenesis in the rat by green tea. Cancer Lett, 112: 149-154.
131. Qin, G, Ning, Y, and, Lotlikar, P D. 2000. Chemoprevention of aflatoxin B 1-initiated and carbon tetrachloride-promoted hepatocarcinogenesis in the rat by green tea. Nutr Cancer, 38: 215-222.
132. Bishayee, A, and, Chatterjee, M. 1995. Inhibitory effect of vanadium on rat liver carcinogenesis initiated with diethylnitrosoamine and promoted with phenobarbital. Br J Cancer, 71: 1214-1220.
133. Bishayee, A, Sarkar, A, and, Chatterjee, M. 2000. Further evidence for chemopreventive potential of beta-carotene against experimental carcinogenesis: diethylnitrosoamine-initiated and phenobarbital-promoted hepatocarcinogenesis prevented more affected by beta-carotene than by retinoic acid. Nutr Cancer, 37: 89-98.
134. Bishayee, A, and, Dhir, N. 2009. Resveratrol-mediated chemoprevention of diethylnitrosoamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem Biol Interact, 179: 131-144.
135. Li, Y. 1991. Comparative study on the inhibitory effect of green tea, coffee and levamisole on the hepatocarcinogenic action of diethylnitrosamine. Zhonghua Zhong Liu Zu Zhi, 13: 193-195.
136. Hirose, M, Hoshiya, T, Akagi, K, Takahashi, S, Hara, Y. 1993. Effects of green tea catechins in a rat multi-organ carcinogenesis model. Carcinogenesis, 14: 1549-1553.
137. Hirose, M, Hasegawa, R, Kimura, J, Akagi, K, Yoshida, Y. 1995. Inhibitory effects of 1-O-hexyl-2,3,5-trimethylhydroquinone (HTHQ), green tea catechins and other antioxidants on 2-amino-6-methyldipyrido[1,2-a:3′,2′-d] imidazole (Glu-P-1)-induced rat hepatocarcinogenesis and dose-dependent inhibition by HTHQ of lesion induction by Glu-P-1 or 2-amino-3,8- dimethylinidazo[4,5- f ]quinoxaline (MeIQx). Carcinogenesis, 16: 3049-3055.
138. Hirose, M, Futakuchi, M, Tanaka, H, Orita, S I, Ito, T. 1998. Prevention by antioxidants of heterocyclic amine-induced carcinogenesis in a rat medium-term liver bioassay: results of extended and combination treatment experiments. Eur J Cancer Prev, 7: 61-67.
139. Hirose, M, Takahashi, S, Ogawa, K, Futakuchi, M, Shirai, T. 1999. Chemoprevention of heterocyclic amine-induced carcinogenesis by phenolic compounds in rats. Cancer Lett, 143: 173-178.
140. Cao, J, Xu, Y, Chen, J, and, Klaunig, J E. 1996. Chemopreventive effects of green and black tea on pulmonary and hepatic carcinogenesis. Fundam Appl Toxicol, 29: 244-250.
141. Matsumoto, N, Kohri, T, Okushio, K, and, Hara, Y. 1996. Inhibitory effects of tea catechins, black tea extract and oolong tea extract on hepatocarcinogenesis in rat. Jpn J Cancer Res, 87: 1034-1038.
142. Tamura, K, Nakae, D, Horiguchi, K, Akai, H, Kobayashi, Y. 1997. Inhibition by green tea extract of diethylnitrosamine-initiated but not choline-deficient, L-amino acid-defined diet-associated development of putative preneoplastic, glutathione S-transferase placental form-positive lesions in rat liver. Jpn J Cancer Res, 88: 356-362.
143. Umemura, T, Kai, S, Hasegawa, R, Kanki, K, Kitamura, Y. 2003. Prevention of dual promoting effects of pentachlorophenol, an environmental pollutant, on diethylnitrosamine-induced hepato- and cholangiocarcinogenesis in mice by green tea infusion. Carcinogenesis, 24: 1105-1109.
144. Kim, H S, Kim, H S, and, Choi, H. 2008. Pre- and post-initiation modulating effects of green tea ingestion on rat hepatocarcinogenesis. Nutr Res Prac, 2: 234-239.
145. Marnewick, J L, van der Westhuizen, F H, Joubert, E, Swanevelder, S, Swart, P. 2009. Chemopreventive properties of rooibos (Aspalathus linearis), honeybush (Cyclopia intermedia) herbal and green and black (Camellia sinensis) teas against cancer promotion induced by fumonisin B1 in rat liver. Food Chem Toxicol, 47: 220-229.
146. Srivastava, S, Singh, M, Roy, P, Prasad, S, George, J. 2009. Inhibitory effect of tea polyphenols on hepatic preneoplastic foci in Wistar rats. Investig New Drugs, 27: 526-533.
147. Tharappel, J C, Lehmler, H J, Srinivasan, C, Robertson, L W, Spear, B T. 2008. Effect of antioxidant phytochemicals on the hepatic tumor promoting activity of 3,3′,4,4′-tetrachlorobiphenyl (PCB-77). Food Chem Toxicol, 46: 3467-3474.
148. Shimizu, M, Sakai, H, Shirakami, Y, Yasuda, Y, Kubota, M. 2011. Preventive effects of (-)-epigallocatechin gallate on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice. Cancer Prev Res, 4: 396-403.
149. González de Mejía, E, Ramírez-Mares, M V, Arce-Popoca, E, Wallig, M, and, Villa-Treviño, S. 2004. Inhibition of liver carcinogenesis in Wistar rats by consumption of an aqueous extract from leaves of Ardisia compressa. Food Chem Toxicol, 42: 509-516.
150. Chung, F L, Wang, M, Rivenson, A, Iatropoulos, M J, Reinhardt, J C. 1998. Inhibition of lung carcinogenesis by black tea in Fischer rats treated with a tobacco-specific carcinogen: caffeine as an important constituent. Cancer Res, 58: 4096-4101.
151. Murugan, R S, Uchida, K, Hara, Y, and, Nagini, S. 2008. Black tea polyphenols modulate xenobiotic-metabolizing enzymes, oxidative stress and adduct formation in a rat hepatocarcinogenesis model. Free Rad Res, 42: 873-884.
152. Murugan, R S, Vinothini, G, Hara, Y, and, Nagini, S. 2009. Black tea polyphenols target matrix metalloproteinases RECK, proangiogenic molecules and histone deacetylase in a rat hepatocarcinogenesis model. Anticancer Res, 29: 2301-2305.
153. Zhang, G, Miura, Y, and, Yagasaki, K. 2002. Effects of dietary powdered green tea and theanine on tumor growth and endogenous hyperlipidemia in hepatoma-bearing rats. Biosci Biotechnol Biochem, 66: 711-716.
154. Chakraborty, T, Chatterjee, A, Rana, A, Dhachinamoorthi, D, Kumar, P A. 2007. Carcinogen-induced early molecular events and its implication in the initiation of chemical hepatocarcinogenesis in rats: chemopreventive role of vanadium on this process. Biochem Biophys Acta, 1772: 48-59.
155. Verna, L, Whysner, J, and, Williams, G M. 1996. N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Pharmacol Ther, 71: 57-81.
156. Li, X, Zhou, X P, Guan, Y S, and, Wang, Y X. 2005. Magnetic resonance imaging of hepatocellular carcinoma induced by diethylnitrosamine in Sprague-Dawley rats. Hepatobiliary Pancreat Dis Int, 4: 427-432.
157. Lee, J S, Chu, I S, Mikaelyan, A, Calvisi, D F, Heo, J. 2004. Application of functional genomics to identify best-fit mouse models to study human cancer. Nat Genet, 36: 1306-1311.
158. Kerbel, R S. 2003. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther, 2: S134-S139.
159. Aggarwal, B B, Danda, D, Gupta, S, and, Gehlot, P. 2009. Models for prevention and treatment of cancer: problems vs promises. Biochem Pharmacol, 78: 1083-1094.
160. Caderni, G, De Filippo, C, Luceri, C, Salvadori, M, Giannini, A. 2000. Effects of black tea, green tea and wine extracts on intestinal carcinogenesis induced by azoxymethane in F344 rats. Carcinogenesis, 21: 1965-1969.
161. Chow, H H, Hakim, I A, Vining, D R, Crowell, J A, Ranger-Moore, J. 2005. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of polyphenon E in healthy individuals. Clin Cancer Res, 11: 4627-4633.
162. Lambert, J D, Lee, M J, Diamond, L, Ju, J, Hong, J. 2006. Dose-dependent levels of epigallocatechin-3-gallate in human colon cancer cells and mouse plasma and tissues. Drug Metab Dispos, 34: 8-11.
163. Jin, X, Zheng, R-H, and, Li-YM. 2008. Green tea consumption and liver disease: a systematic review. Liver Int, 28: 990-996.
164. Luo, H, Tang, L, Tang, M, Billam, M, Huang, T. 2006. Phase IIa chemoprevention trial of green tea polyphenols in high-risk individuals of liver cancer: modulation of urinary excretion of green tea polyphenols and 8-hydrodeoxyguanosine. Carcinogenesis, 27: 262-268.